Description

Retatrutide an investigational triple-agonist compound studied for its activity at three hormone receptors: GLP-1, GIP, and Glucagon (GCGR).  In clinical and preclinical research, GLP-1 and GIP agonism have been associated with appetite suppression, slowed gastric emptying and improved glycemic control.  Glucagon receptor activity studied for its role in increasing energy expenditure and promoting breakdown of stored fat and hepatic fat clearance.  Retatrutide remains under clinical investigation and is not an approved pharmaceutical Rx product.

• For Research use only
• Not for human use
• Independent Lab Tested